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diagnosis of either leukemia, melanoma, or non-small cell lung cancer (NSCLC) 
and reported currently using a treatment for their condition were included in the 
analyses. Adherence was measured using the Morisky Medication Adherence 
Scale (MMAS-8) modified for use in oncology. Sociodemographics, health history, 
and health outcomes were also assessed. Descriptive analyses of adherence were 
conducted along with an assessment of the relationships between adherence 
and health outcomes. RESULTS: A total of 103 respondents were included in the 
analyses (n=42, 41, and 20 for leukemia, melanoma, and NSCLC, respectively). 
Most respondents were male (69.9%) and the mean age was 57.1 years (SD=15.79). 
Across the three tumor types 65.0% of respondents reported some form of non-
adherent behavior (71.4%, 58.5%, and 65.0% for leukemia, melanoma, and NSCLC, 
respectively). Pooling tumor types, patients who were non-adherent reported 
significantly worse mental health status compared with patients who were 
adherent (Mean=44.41 vs. 49.48, p<.05). Similar trends (though only marginally 
significant) were observed for hospitalizations (Mean=0.97 vs. 0.42, p=.11) and 
emergency room visits (Mean=1.18 vs. 0.25, p=.07) in the past six months. 
CONCLUSIONS: These results suggest a significant level of non-adherence 
among patients being treated for leukemia, melanoma, and NSCLC. Although 
statistical power was modest due to small sample size, preliminary results 
suggest a deleterious effect of non-adherence on health outcomes. As more oral 
targeted therapies emerge, an emphasis should be placed on improving 
adherence rates to maximize treatment benefit and reduce societal costs.  
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OBJECTIVES: The aim of our study was to evaluate a sample of the population’s 
knowledge on cervical smear test and HPV, also learn about the vaccine, 
attitudes towards screening, the appearance at screening or absence 
motivations. METHODS: A quantitative cross-sectional, questionnaire survey 
was carried out among the mothers of girls aged nine to fourteen years in the 
public school of Nagyatád town in September 2012. In total, 247 questionnaires 
were distributed, of which 186 proved to be evaluated. The χ2-test was performed 
as a statistical method besides 95% probability (p<0.05). The data analysis was 
performed with SPSS 20.0 programs. RESULTS: 96.2% of the respondent women 
have had cervical smear tests. Their average age was 20.92 years when they went 
for the first time for cervical cancer screening. 84.4% of respondent women 
reported annual visit for screening. 49.2% of respondent women last appeared in 
2012, while 40.2% in 2011 at gynecologist. College graduates were significantly (χ2 
= 13.785, p = 0.032) less likely to take part on screening over two years interval. 
Most of their knowledge on the prevention of cervical cancer obtained from 
television (67.7%), gynecologist (58.6%), Internet (47.8%) or newspapers (36%). 
Only 8.1% had heard of the disease in the form of lectures. CONCLUSIONS: 
Women reported a very high participation rate at cervical cancer screening. 
Although there is a three years screening interval in Hungary, most of the 
women in our study reported a two years or less screening interval.  
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OBJECTIVES: To elicit utility values for CML chronic phase health states (i.e. 
molecular response (MR), complete molecular response (CMR) [i.e. undetectable 
disease on treatment], treatment-free remission (TFR) and re-appearance of 
detectable disease (RDD) [i.e. relapse from treatment-free remission to molecular 
response requiring treatment]) from the general public in the UK. METHODS: 
Interviewer-administered time trade-off (TTO) and standard gamble (SG) utilities 
were elicited for four CML-related health states from a random sample of 235 
members of the general public in the UK, using health state descriptions 
validated by clinicians and members of the general public. RESULTS: 
Respondents’ mean age was 61 years and 47% were female. Mean utilities were: 
0.90 (TTO) and 0.72 (SG) for RDD, 0.94 (TTO) and 0.80 (SG) for MR, 0.96 (TTO) and 
0.85 (SG) for CMR and 0.97 (TTO) and 0.87 (SG) for TFR. SG values were all 
significantly lower than TTO values (p <0.001). TTO values for TFR and CMR were 
significantly different from that for RDD (p = 0.002). The SG value for TFR was 
significantly different from that for MR and RDD (p <0.001). Additionally, the SG 
value for MR was significantly different from that for CMR (p = 0.02) and RDD (p 
<0.001). Respondents’ preference values for any of the states were not affected by 
their demographics, except SG values elicited from males which were ~0.08 
higher than those from females (p <0.05). CONCLUSIONS: These findings 
suggests that level of response to treatment impacts on patients’ health-related 
quality of life in CML. Health states associated with a better outcome (e.g. TFR) 
were associated with a higher preference value than states with a poorer 
outcome (e.g. RDD). These utility values can be used to estimate quality-adjusted 
life years associated with different treatment options.  
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OBJECTIVES: To determine the relationship between a man’s current urinary and 
sexual function, qualitative valuations of future loss of function, and preferences 
for potential urinary and sexual impairment should he undergo screening or 
treatment for prostate cancer. METHODS: We elicited time-tradeoff utilities for 
prostate cancer treatment outcomes from 168 men. We performed logistic 
regression to (1) analyze the relationships between current function, valuation of 
future loss of function, and preferences, and (2) identify the relationship between 
the qualitative responses and the optimal decision of whether to undergo 
screening for prostate cancer as determined from a previously-published 
decision-analytic model. RESULTS: Current function was not related to 
impotence and urinary incontinence utilities. Importance of sexual function and 
anticipated adjustment to a loss of sexual function were strongly related to 
impotence utilities (P<0.05). Greater perceived difficulty adjusting to loss of 
bladder control, an anticipated function, was significantly related to 
incontinence utilities. Based on the multivariate analysis, significant predictors 
for the utility of severe incontinence were family income (OR=0.26 [CI 0.08-0.87] 
for income $20k-$70k and OR=0.11 [CI 0.01-0.70] for income >$70k, relative to 
income group <$20k), family history of prostate cancer (OR=2.85 [CI 0.96-8.45]), 
work status (OR=2.90 [CI 0.99-8.50]), and attitude toward needing to wear an 
incontinence pad (OR=6.47 [CI 0.76-54.4]). However, no variables were significant 
predictors for the complete impotence utilities. The importance of sexual 
functioning, with odds of 2.99 ([CI 1.28-6.95]), was a significant predictor of the 
optimal decision to screen. CONCLUSIONS: Current function and satisfaction are 
not necessarily useful as proxy measures of utility; however, anticipated 
difficulty adjusting to adverse health effects were highly related to preferences. 
Similarly, the importance of sexual functioning, a future preference, was related 
to the optimal decision, which validates our previously published decision-
analytic model.  
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OBJECTIVES: Excess weight is associated with poorer disease outcomes across 
various cancers. The current study examined health outcomes associated with 
obesity in respondents with and without cancer, addressing a lack of large-scale, 
population-based research including non-cancer comparison groups. METHODS: 
Among 71,149 U.S. 2012 NHWS respondents, 7,751 reported diagnosis with 
cancer: any/metastatic solid tumor, leukemia, lymphoma, breast, cervical, 
colorectal, ovarian, prostate, skin, uterine, other, small cell lung, and/or non-
small cell lung cancer. Cancer diagnosis and obesity (BMI≥30 vs. less) were 
crossed for analysis, resulting in 69,292 respondents (excluding 1,857 without 
BMI information): 2,745 obese versus 4,860 non-obese with cancer and 20,177 
obese versus 41,510 non-obese without cancer. Health outcomes included Work 
Productivity and Activity Impairment questionnaire-based measures (among 
employed-only for work productivity), and Mental and Physical Component 
Summary (MCS and PCS) scores and health utilities (SF-6D) from the SF-36v2. 
Bivariate tests of column proportions and means for categorical and continuous 
variables, respectively, compared measures across all groups. Multivariable 
(linear and negative binomial) generalized linear models assessed outcomes as a 
function of obesity, cancer diagnosis, their interaction, and sociodemographic 
and health behavior covariates of interest, plus Charlson comorbidity index (CCI) 
scores. RESULTS: Respondents with versus without cancer were older and had 
higher CCI (as did obese versus non-obese respondents), all p<0.05. Adjusting for 
covariates, obesity versus no obesity was associated (among those with cancer) 
with decreases in PCS (-3.61 points) and utilities (-0.030) and increases in 
presenteeism-related (20%), overall work (18%), and activity (24%) impairment, 
all p<0.05. CCI was associated with significant impairments across outcomes, all 
p<0.001. CONCLUSIONS: Among cancer-diagnosed respondents, obesity was 
associated with significant impairments. Obese respondents with cancer also 
had a higher rate of comorbidity. Obesity and a history of cancer may represent a 
”dual-risk” profile, suggesting the need for coordinated follow-up care and health 
promotion in this population.  
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OBJECTIVES: To evaluate the concordance between Neurocognitive function 
(NCF), Karnofsky performance status (KPS), quality of life and time trade-off 
(TTO) over time. METHODS: We retrospectively analyzed secondary data from a 
randomized study of 58 patients who completed tests determining TTO utility 
with each of three time horizons (10 years, 5 years, and 1 year), neurocognitive 
function (Hopkins Verbal Learning Test–Revised [HVLT-R] and Trail Making Test 
Part B), KPS score, and quality of life (Functional Assessment of Cancer Therapy–
Brain [FACT-BR]) and symptoms (MD Anderson Symptom Inventory–Brain Tumor 
[MDASI-BT]) at baseline and at predetermined intervals for 2 years. Multiple 
linear regression analyses were used to estimate the relationships between TTO 
utility and other outcome variables, including a time variable to capture within-
patient change over time. RESULTS: Significant but weak associations were 
